Кардиоваскулярная терапия и профилактика

Расширенный поиск

Тактика лечения при неэффективности монотерапии статинами

Полный текст:


Представлены механизмы воздействия на всасывание холестерина. Рассмотрены ограничения при проведении монотерапии статинами и преимущества использования комбинации статин + эзетимиб.

Об авторе

И. В. Сергиенко
ФГУ Российский кардиологический научно-производственный комплекс

с.н.с. отдела проблем атеросклероза

Москва, Тел.: 495)414-72-86, 8-903-149-22-53

Список литературы

1. Howles PN. Cholesterol Absorption and Metabolism. Methods in Molecular Biology 2010; 602: 157-79.

2. Kastelein JJ, van Leuven SI, Burgess L, et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007; 356: 1620-30.

3. Forrester JS, Makkar R, Shah PK. Increasing high-density lipoprotein cholesterol in dyslipidemia by cholesteryl ester transfer protein inhibition. Circulation 2005; 111: 1847-54.

4. Tchoua U, Souza W, Mukhamedova N, et al. The effect of cholesteryl ester transfer protein overexpression and inhibition on reverse cholesterol transport. Cardiovasc Res 2008; 77: 732-9.

5. VanHeek M, France CF, Compton DS, et al. In vivo metabolism-based discovery of a potent absorption cholesterol inhibitor, SCH58235, in the rat, and rhesus monkey through the identification of the active metabolites of SCH48461. J Pharmacol Exp Therap 1997; 283: 157-63.

6. Altmann SW, Davis HR, Zhu L, et al. Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption. Science 2004; 303: 1201-4.

7. Garcia-Calvo M, Lisnock HG, Bull BE, et al. The target of ezetimibe is Niemann-Pick C1-like 1 (NPC1L1). Proc Natl Acad Sci 2005; 102: 8132-7.

8. Ziajka PE, Reis M, Kreul S, et al. Initial low-density lipoprotein response to statin therapy predicts subsequent low-density lipoprotein response to the addition of ezetimibe. Am J Cardiol 2004; 93: 779-80.

9. Pedro-Botet J, Schaefer EJ, Bakker-Arkema RG, et al. Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner. Atherosclerosis 2001; 158: 183-93.

10. Van Himbergen TM, Matthan NR, Resteghini NA, et al. Comparison of the effects of maximal dose atorvastatin and rosu vastatin therapy on cholesterol synthesis and absorption markers. J Lipid Res 2009; 50: 730-9.

11. Lamon-Fava S, Diffenderfer MR, Barrett PH, et al. Effects of different doses of atorvastatin on human apolipoprotein B-100, B-48, and A-I metabolism. J Lipid Res 2007; 48(8): 1746-53.

12. Matthan NR, Resteghini N, Robertson M, et al. Cholesterol absorption and synthesis markers in individuals with and without a CHD event during pravastatin therapy: insights from the PROSPER trial. J Lipid Res 2010; 51(1): 202-9.

13. Ooi Esther MM, Barrett P, Chan DC. Dose-dependent effect of rosuvastatin on apolipoprotein B-100 kinetics in the metabolic syndrome. Atherosclerosis 2008; 197(1): 139-46.

14. Jakulj L, Trip MD, Sudhop T, von Bergmann K, Kastelein JJ. Inhibition of cholesterol absorption by the combination of dietary plant sterols and ezetimibe: effects on plasma lipid levels. J Lipid Res 2005; 46: 2692-8.

15. Sudhop Th, Lßtjohann D, Kodal A, et al. Inhibition of Intestinal Cholesterol Absorption by Ezetimibe in Humans. Circulation 2002; 106: 1943-8.

16. Clarenbach JJ, Reber M, Lutjohann D, et al. The lipid-lowering effect of ezetimibe in pure vegetarians. J Lipid Res 2006; 47(12): 2820-4.

17. Murphy SA, Cannon CP, Wiviott SD, et al. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndrome. JACC 2009; 54: 2358-62.

18. Farnier M, Averna M, Missault L, et al. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy-the IN-CROSS study. Int J Clin Pract 2009; 63(4): 547-59.

19. McCormack T, Harvey P, Gaunt R, et al. IN-PRACTICE study. “Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets”. Int J Clin Pract 2010; 64 (8): 1052-61.

20. Ballantyne CM, John H, Alberto N, et al. Effect of Ezetimibe Coadministered With Atorvastatin in 628 Patients With Primary Hypercholesterolemia: A Prospective, Randomized, DoubleBlind Trial. Circulation 2003; 107: 2409-15.

21. Ose L, Shah A, Davies MJ, et al. Consistency of lipid-altering effects of ezetimibe/simvastatin across gender, race, age, baseline low density lipoprotein cholesterol levels, and coronary heart disease status: results of a pooled retrospective analysis. Curr Med Res Opin 2006; 22(5): 823-35.

22. Conard SE, Bays HE, Leiter LA, et al. Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease. Am J Cardiol 2008; 102(11): 1489-94.

23. Leiter LA, Bays H, Conard S, et al. Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease. Am J Cardiol 2008; 102: 1495-501.

24. Kastelein JJ, Akdim F, Stroes ESG, et al. Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia. N Engl J Med 2008; 358: 1431-43.

25. Brown BG, Taylor AJ. Does ENHANCE Diminish Confidence in Lowering LDL or in Ezetimibe? N Engl J Med 2008; 358: 1504-7.

26. Drazen JM, Jarcho JA, Morrissey S, Curfman GD. Cholesterol Lowering and Ezetimibe. N Engl J Med 2008; 358: 1507-8.

27. Fleg JL, Mete M, Howard BV, et al. Effect of Statins Alone Versus Statins Plus Ezetimibe on Carotid Atherosclerosis in Type 2 Diabetes The SANDS (Stop Atherosclerosis in Native Diabetics Study) Trial. JACC 2008; 52: 2198-205.

28. McGinnis B, Schimmer J, Hutka K. An evaluation of alanine transaminase and creatine kinase elevations with the use of ezetimibe in an ambulatory care setting. J Clin Lipidol 2010; 4(6): 501-7.

29. Rossebo AB, Pedersen TR, Boman K, et al. Intensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis. N Engl J Med 2008; 359: 1343-56.

30. Gerdts E, Anne Bjorhovde Rossebo AB, Pedersen TR. Impact of Baseline Severity of Aortic Valve Stenosis on Effect of Intensive Lipid Lowering Therapy (from the SEAS Study). J Am Cardiol, 2010, 106(11): 1634-9.

31. Zoghbi WA. Low-Gradient “Severe” Aortic Stenosis With Normal Systolic Function Time to Refine the Guidelines? Circulation 2011; 123: 838-40.

32. Peto R, Emberson J, Landrey M, et al. Analyses of cancer data from three ezetimibe trials. N Engl J Med 2008; 359: 1357-66.

33. Leiter LA, Betteridge DJ, Farnier M, et al. Lipid-altering efficacy and safety profile of combination therapy with ezetimibe/statin versus statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials. Diabetes Obes Metab 2011; Feb 18. doi: 10.1111/j.1463-1326.2011.01383.x.

34. Avellone G, Di Garbo V, Guarnotta V, et al. Efficacy and safety of long-term ezetimibe/simvastatin treatment in patients with familial hypercholesterolemia. Int Angiol 2010; 29(6): 514-24.

Для цитирования:

Сергиенко И.В. Тактика лечения при неэффективности монотерапии статинами. Кардиоваскулярная терапия и профилактика. 2011;10(4):110-116.

For citation:

Sergienko I.V. Ineffective statin monotherapy: alternative therapeutic strategy. Cardiovascular Therapy and Prevention. 2011;10(4):110-116. (In Russ.)

Просмотров: 27

Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.

ISSN 1728-8800 (Print)
ISSN 2619-0125 (Online)